Genzyme Licenses Gene Therapy Candidate For Parkinson’s Disease
Ceregene deal worth up to $150 million plus future research reimbursements for the Phase II candidate.
Ceregene deal worth up to $150 million plus future research reimbursements for the Phase II candidate.